scholarly journals Sambiloto (Andrographis Paniculata) Increases Glucagon–Like Peptide 1 Concentration in Prediabetes: A Double–Blind, Randomized, Placebo-Controlled Trial

2020 ◽  
Author(s):  
Tri Juli Edi Tarigan ◽  
Erni Hernawati Purwaningsih ◽  
Yusra Yusra ◽  
Murdani Abdullah ◽  
Nafrialdi Nafrialdi ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Controlled Trial ◽  
Glycated Albumin ◽  
Fasting Blood Glucose ◽  
Postprandial Blood Glucose ◽  
Fasting Insulin ◽  
Double Blind ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Postprandial Insulin

Abstract Background : The extract of Andrographis paniculata (Burm. F.) Wall. Ex. Nees. (sambiloto) (穿心蓮 chuān xīn lián) has been reported to have antidiabetic effect on mice models and has been used traditionally in the community. The exact mechanism of sambiloto extract in decreasing plasma glucose is unclear, so we investigated the role of sambiloto extract in incretin pathway in healthy and prediabetes subjects.Methods: This study was a double-blind, cross-over, randomized placebo-controlled trial. It was conducted to 38 healthy and 35 prediabetes subjects. All subjects were exposed to both intervention sambiloto extract and placebo alternately. All subjects were randomly assigned to receive first intervention for 14 days. There was wash out period between subsequent intervention. Primary outcome was glucagon-like peptide 1 (GLP-1) concentration and secondary outcomes were fasting insulin, 2-hour postprandial insulin, homeostasis model assessment of insulin resistance (HOMA-IR), fasting blood glucose, 2-hour postprandial blood glucose, dipeptidyl peptidase-4 (DPP-4), and glycated albumin before and after intervention.Result: After the intervention, GLP-1 concentration significantly increased in prediabetes by 19.6% compared to the placebo (p = 0.043). There were no significant differences in the changes of fasting insulin, 2-hour postprandial insulin, HOMA-IR, fasting blood glucose, 2-hour postprandial blood glucose, DPP-4, and glycated albumin levels after intervention. Sambiloto extract did not inhibit DPP-4 enzyme in healthy and prediabetes subjects. Conclusion: Sambiloto extract increased GLP-1 concentration without inhibiting DPP-4 enzyme in prediabetes subjects.Trial Registration : Clinical Trials.gov ID : NCT03455049. Registered 6 March 2018 – Retrospectevly Registered, https://clinicaltrials.gov/ct2/show/NCT03455049.

scholarly journals Effects of Sambiloto (Andrographis paniculata) on GLP-1 and DPP-4 Concentrations between Normal and Prediabetic Subjects: A Crossover Study

2022 ◽  
Vol 2022 ◽  
pp. 1-7
Author(s):  
Tri Juli Edi Tarigan ◽  
Erni Hernawati Purwaningsih ◽  
Yusra ◽  
Murdani Abdullah ◽  
Nafrialdi ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glycated Albumin ◽  
Fasting Blood Glucose ◽  
Andrographis Paniculata ◽  
Postprandial Blood Glucose ◽  
Model Assessment ◽  
Fasting Insulin ◽  
Double Blind ◽  
To Receive ◽  
Postprandial Insulin

Background. The extract of Andrographis paniculata (Burm. F.) Wall. Ex. Nees. (sambiloto) (穿心蓮 chuān xīn lián) has been reported to have an antidiabetic effect on mice models and has been used traditionally in the community. The exact mechanism of sambiloto extract in decreasing plasma glucose is unclear, so we investigated the role of sambiloto extract in the incretin pathway in healthy and prediabetic subjects. Methods. This study was a randomized, placebo-controlled, crossover, double-blind trial. It included 38 people who were healthy and 35 people who had prediabetes. All subjects were randomly assigned to receive either the intervention sambiloto extract or a placebo. All subjects were randomly assigned to receive the first intervention for 14 days. There was a washout period between subsequent interventions. The primary outcome was glucagon-like peptide 1 (GLP-1) concentration, and secondary outcomes were fasting insulin, 2-hour postprandial insulin, homeostasis model assessment of insulin resistance (HOMA-IR), fasting blood glucose, 2-hour postprandial blood glucose, dipeptidyl peptidase-4 (DPP-4), and glycated albumin before and after the intervention. Result. After the intervention, GLP-1 concentration significantly increased in prediabetes by 19.6% compared to the placebo ( p = 0.043 ). There were no significant differences in the changes of fasting insulin, 2-hour postprandial insulin, HOMA-IR, fasting blood glucose, 2-hour postprandial blood glucose, DPP-4, and glycated albumin levels after the intervention. Sambiloto extract did not inhibit the DPP-4 enzyme in healthy and prediabetic subjects. Conclusion. Sambiloto extract increased GLP-1 concentration without inhibiting the DPP-4 enzyme in prediabetic subjects. This trial is registered with ClinicalTrials.gov (ID: NCT03455049), registered on 6 March 2018—retrospectively registered (https://clinicaltrials.gov/ct2/show/NCT03455049).

Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial

Nutrition ◽  
2018 ◽  
Vol 55-56 ◽  
pp. 125-130 ◽  
Author(s):  
Amornpan Lertrit ◽  
Sasinee Srimachai ◽  
Sunee Saetung ◽  
Suwannee Chanprasertyothin ◽  
La-or Chailurkit ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals A randomized, double-blind, placebo-controlled trial to evaluate the hypoglycemic efficacy of the mcIRBP-19-containing Momordica charantia L. fruit extracts in the type 2 diabetic subjects

2022 ◽  
Author(s):  
Yi-Sun Yang ◽  
Nian-Yi Wu ◽  
Edy Kornelius ◽  
Chien-Ning Huang ◽  
Nae-Cherng Yang
Keyword(s):  
Blood Glucose ◽  
Animal Studies ◽  
Controlled Trial ◽  
Fasting Blood Glucose ◽  
Momordica Charantia ◽  
Antidiabetic Drugs ◽  
Bitter Gourd ◽  
Double Blind

Background: The fruits of Momordica charantia L., also named as bitter gourd or bitter melon in popular, is a common tropical vegetable that is traditionally used to reduce blood glucose. A peptide derived from bitter gourd, Momordica charantia insulin receptor binding peptid-19 (mcIRBP-19), had been demonstrated to possess an insulin-like effect in vitro and in the animal studies. However, the benefit of the mcIRBP-19-containing bitter gourd extracts (mcIRBP-19-BGE) for lowering blood glucose levels in humans is unknown. Objective: This aim of this study was to evaluate the hypoglycemic efficacy of mcIRBP-19-BGE in subjects with type 2 diabetes who had taken antidiabetic medications but failed to achieve the treatment goal. Whether glucose lowering efficacy of mcIRBP-19-BGE could be demonstrated when the antidiabetic medications were ineffective was also studied. Design: Subjects were randomly assigned to two groups: mcIRBP-19-BGE treatment group (N = 20) and placebo group (N = 20), and were orally administered 600 mg/day investigational product or placebo for 3 months. Subjects whose hemoglobin A1c (HbA1c) continued declining before the trial initiation with the antidiabetic drugs were excluded from the subset analysis to further investigate the efficacy for those who failed to respond to the antidiabetic medications. Results: The oral administration of mcIRBP-19-BGE decreased with a borderline significance at fasting blood glucose (FBG; P = 0.057) and HbA1c (P = 0.060). The subgroup analysis (N = 29) showed that mcIRBP-19-BGE had a significant effect on reducing FBG (from 172.5 ± 32.6 mg/dL to 159.4 ± 18.3 mg/dL, P = 0.041) and HbA1c (from 8.0 ± 0.7% to 7.5 ± 0.8%, P = 0.010). Conclusion: All of these results demonstrate that mcIRBP-19-BGE possesses a hypoglycemic effect, and can have a significant reduction in FBG and HbA1c when the antidiabetic drugs are ineffective.

Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management

2017 ◽  
Vol 51 (5) ◽  
pp. 401-409 ◽  
Author(s):  
Delilah McCarty ◽  
Megan Coleman ◽  
Cassie L. Boland
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Gastric Emptying ◽  
Diabetes Management ◽  
Human Subjects ◽  
Data Extraction ◽  
Postprandial Blood Glucose ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist (GLP-1RA), lixisenatide, in the treatment of type 2 diabetes mellitus. Data Sources: A PubMed (1966-2016) search was conducted using the following keywords: lixisenatide, AVE0010, glucagon-like peptide-1 agonist, and type 2 diabetes. References were reviewed to identify additional sources. Study Selection and Data Extraction: Articles written in English were included if they evaluated the pharmacology, pharmacokinetics, efficacy, or safety of lixisenatide in human subjects. Data Synthesis: Lixisenatide lowers blood glucose through a glucose-dependent increase in insulin release from pancreatic β-cells and a decreased release of glucagon from pancreatic α-cells. Additionally, lixisenatide delays gastric emptying and increases satiety. Lixisenatide has been studied head to head against exenatide and insulin glulisine. It has also been studied as monotherapy and in combination with metformin, sulfonylureas, pioglitazone, and insulin glargine. In the GetGoal clinical trial series, lixisenatide resulted in a hemoglobin A1C reduction of 0.6% to 1% and a reduction in body weight of 0.2 to 2.96 kg. The adverse effect profile of lixisenatide was consistent with that of other GLP-1RAs, with nausea, vomiting, and diarrhea most commonly reported. Conclusion: Lixisenatide provides an additional GLP-1RA option, which may have more postprandial blood glucose-lowering effects than the other agents in the class because of its shorter half-life and effects on delaying gastric emptying.

scholarly journals Improvement of glucose metabolism and safety of acacia bark-derived proanthocyanidins in healthy Japanese adults: A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial

2021 ◽  
Vol 11 (9) ◽  
pp. 431
Author(s):  
Asami Baba ◽  
Tomohiro Hoshino ◽  
Sosuke Ogawa ◽  
Tsuyoshi Takara
Keyword(s):  
Placebo Group ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Skin Condition ◽  
Postprandial Blood Glucose ◽  
Bark Extract ◽  
Double Blind ◽  
Beneficial Effects ◽  
Glucose Levels ◽  
Japanese Adults

Objective: Acacia bark-derived proanthocyanidins exhibit antioxidant, anti-inflammatory, anti-diabetic, hypotensive effects, and improving skin condition, in addition to beneficial effects on blood glucose. Herein, we evaluated the effects of acacia bark-derived proanthocyanidins on fasting and postprandial blood glucose levels in healthy Japanese adults with fasting blood glucose (FBG) levels between 110–125 mg/dL.Methods: Subjects were randomly allocated into 2 groups (n = 33 per group) and consumed 6 tablets/day of either tablets of acacia bark extract containing proanthocyanidins (Acacia group) or placebo for 12 weeks. Evaluation points were at the screening, and after 4-week (4w), 8-week (8w), and 12-week intervention (12w). The primary outcome was FBG level at 12 w, whereas the secondary outcomes were FBG level at 4w and 8w, the FBG changes from Scr to each-week intervention, the percentage of subjects with FBG levels below 110 mg/dL after 12 w, the measured value and the change value from Scr to each-week intervention of HbA1c, the measured value and the change value from Scr to each-week intervention of postprandial blood glucose levels.Results: A total of 33 subjects (18 men, 15 women) from each group were analyzed. The Acacia group had significantly lower FBG levels at 8 and 12 w than the placebo group (P = 0.030 and P = 0.014, respectively). The percentage of subjects with FBG <110 mg/dL at 12 w was marginally higher in the Acacia group than in the placebo group (P = 0.079). HbA1c at 12 w was significantly lowered in the Acacia group compared to the placebo group (P = 0.015).Conclusions: Acacia bark-derived proanthocyanidins were confirmed to have FBG-lowering effects.Trial registration: UMIN000039414Foundation: Acacia-No-Ki Co.,Ltd.Keywords: Acacia bark extract, Proanthocyanidins, Fasting blood glucose level, HbA1c

scholarly journals Efek konsumsi yogurt terhadap glukosa darah puasa pada penyandang diabetes melitus tipe 2

2020 ◽  
Vol 8 (1) ◽  
pp. 40
Author(s):  
Farah Nuriannisa ◽  
Nyoman Kertia ◽  
Lily Arsanti Lestari
Keyword(s):  
Blood Glucose ◽  
Controlled Trial ◽  
Health Centre ◽  
Fasting Blood Glucose ◽  
Intervention Group ◽  
Control Group ◽  
Double Blind ◽  
Significant Difference ◽  
Before And After ◽  
Reduce Blood Glucose

Background: Generally, patients with type 2 diabetes mellitus (T2D) have dysbiosis condition. Dysbiosis can increase oxidative stress that leads to hyperglycemia. Previous researches showed that yogurt consumption can reduce blood glucose in T2D, so it can be used as an alternative healthy snack for T2D patients.Objectives: To investigate the effects of probiotic and conventional yogurt with dosage 100ml/day on fasting blood glucose (FBG) in T2D patientsMethods: Randomized controlled trial, double blind with pre-post group design. The 30 T2D patients from 3 publics health centre in Yogyakarta, were assigned to two groups. Each group, either control or intervention group, received 100 ml/d of yogurt for 4 weeks. FBG samples was assessed before and after intervention periodResults: FBG significantly decreased in both group, which was -27 mg/dL in control group (p<0.05) and -19 mg/dL in intervention group (p<0.05). No significant difference in FBG change between intervention and control group, but control group has greater reduction in FBG compared to intervention group. Conclusion: Conventional yogurt has no significant difference effect in FBG change compared to probiotic yogurt. 

Sign in / Sign up

Export Citation Format

Share Document